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Available online 2 October 2009After spinal cord injury in the adult mammal, axons do not normally regrow and this commonly leads to
paralysis. Retinoic acid (RA) can stimulate neurite outgrowth in vitro of both the embryonic central and
peripheral nervous system, via activation of the retinoic acid receptor (RAR) β2. We show here that regions
of the adult CNS, including the cerebellum and cerebral cortex, express RARβ2. We show that when
cerebellar neurons are grown in the presence of myelin-associated glycoprotein (MAG) which inhibits
neurite outgrowth, RARβ can be activated in a dose dependent manner by a RARβ agonist (CD2019) and
neurite outgrowth can occur via phosphoinositide 3-kinase (PI3K) signalling. In a model of spinal cord injury
CD2019 also acts through PI3K signalling to induce axonal outgrowth of descending corticospinal ﬁbres and
promote functional recovery. Our data suggest that RARβ agonists may be of therapeutic potential for human
spinal cord injuries.
© 2009 Elsevier Inc. Open access under CC BY license. Introduction
There areat least three causes for the lackof axonal outgrowthof CNS
neurons after spinal cord injury. First, the presence of growth inhibiting
molecules, including Nogo-A, myelin-associated glycoprotein (MAG)
and oligodendrocyte myelin glycoprotein (Omgp) (He and Koprivica,
2004). Second, insufﬁciency of growth-promoting factors, which are
well known for their ability to promote neurite outgrowth in vitro and
induce some axonal outgrowth when administered to injured cord (Lu
et al., 2004; Schnell et al., 1994). Third, the lackof anappropriate ‘growth
programme’ by damagedneurons (Kwon and Tetzlaff, 2001). One factor
that can induce such a growth programme is retinoic acid (RA)
signalling. This is mediated by retinoic acid receptors (RARs) and
retinoidX receptors (RXRs), bothofwhichhave three subtypes (α,β and
γ) and various isoforms (Bastien and Rochette-Egly, 2004). Transcrip-
tion occurs when RA binds to an RAR/RXR heterodimer, which then
binds to retinoic acid response elements (RAREs) located in the
regulatory regions of target genes (Bastien and Rochette-Egly, 2004).
It has previously been shown that RARβ2 is required for retinoid
mediated neurite outgrowth. Activation of RARβ2 by retinoids resultsorcoran).
Arrixaca Servicio Murciano de
niversidad de Murcia 30100
netics Institute, University of
irect.com).
license. in neurite outgrowth of cultured embryonic dorsal root ganglia (DRG),
spinal cord and adult DRG (Corcoran et al., 2000; Corcoran et al., 2002;
Corcoran and Maden, 1999; So et al., 2006). In adult RARβ null mice
peripheral axonal regeneration is impeded (So et al., 2006) and when
RARβ2 is transduced into cultured adult rodent spinal cord explants,
which do not express this receptor, neurite outgrowth occurs
(Corcoran et al., 2002). The axons from corticospinal tract (CST)
neurons form the major descending pathway in the dorsal columns of
the spinal cord and their damage results in functional impairments of
some motor tasks. Recently it has been demonstrated that over-
expression of RARβ2 by lentiviral vectors in adult DRG or CST neurons
results in outgrowth of axons and functional recovery in models of
CNS injury (Wong et al., 2006; Yip et al., 2006).
Amuch simpler approach to upregulate RARβ2 expression in vivo is
to use an RARβ agonist as the gene for this receptor contains an RARE,
resulting in autoregulation (Leid et al., 1992). Also, it is a much more
practical solution to treat CNS injuries with a RARβ agonist than with
gene therapy, since it is a small lipophilic molecule which can poten-
tially reach all the injured neurons, and the dose can be controlled.We
show here that a RARβ agonist (CD2019) leads to axonal outgrowth
and functional recovery in a rodent model of spinal cord injury.
Material and methods
Animal surgery
All animal experiments were carried out under UK home ofﬁce
regulations. Dorsal column lesions (DCL) were performed on adult
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pumps ﬂow rate of 0.5 μl/h for 14 days (Alzet) were ﬁlled with 10 μM
RARβ agonist (CD2019, obtained from CIRD Galderma, Sophia-
Antipolis, France), or vehicle (10% DMSO in PBS). This gives a dose of
CD2019of 180ng/kg/day. Thepumpswereplaced subcutaneously and
connected to a brain infusion catheter (Alzet), which was inserted into
the lateral ventricle (Bregma coordinates: rostrocaudal: -0.8 mm,
mediolateral: -1.5 mm and dorsoventral: -4.5 mm). CD2019 is 5-fold
selective for RARβ over RARα and12-fold selective for RARβ over RARγ
(Bernard et al., 1992; Delescluse et al., 1991). The dose was based on
our previous in vivo studies on activation of RARα and β signalling in
the adult rat brain (Goncalves et al., 2009). Animals which underwent
behavioural studies and subsequent tracing (n=6per treatment)were
kept for 6 weeks after lesion before being sacriﬁced with a lethal
injection of pentobarbital and transcardially perfused with 4%
paraformaldehyde (PFA). Dissected tissue (cervical and lumbar spinal
cord) was processed for immunoﬂuoresence.
Western blotting
Protein was extracted from the cortex of adult rats 14 days post-
surgery (n=3 per group). The amount of protein was determined
using a bicinchoninic acid (BCA) protein assay kit (Pierce). Protein
(10 μg) was loaded on 10% or 6% SDS-PAGE gel. Semidry blotting was
performed, and the blots were probed with rabbit anti-RARβ (Santa
Cruz, dilution of 1:500), rabbit anti-phospho-Akt, rabbit anti-Akt (both
from Cell Signalling Technology, dilution of 1:1000), and mouse anti-
GFAP (Sigma, dilution 1:1000). The membranes were then incubated
with HRP-conjugated secondary antibodies (anti-mouse IgM+A
1:5000 from Abcam and anti-mouse and anti-rabbit from Amersham
Pharmacia Biotech 1:5000) and HRP activity was visualized by
applying chemiluminescent substrate (ECL; Amersham Pharmacia
Biotech) followed by exposure of the membrane to X-ray ﬁlm. For a
loading control, the blots were probed with mouse anti-βIII tubulin
(Promega, dilution of 1:1000) and developed as above. The exposed
ﬁlms were analyzed by Gene Tools program (Syngene). Signal density
was calculated as the ratio of signal intensity to β-III tubulin.
RT-PCR
RNA was isolated and cDNA synthesis was carried out as
previously described (Corcoran et al., 2000). For PCR of rat RARβ2
(Accession no. AJ002942) the following primers were used, forward,
ttcgtggacttttctgtgc and reverse, tgtagaaatccaggatctgcc, which yields a
product of 134 bp. These primers are rat RARβ2 speciﬁc and cannot
therefore detect other RAR/RXR isoforms. Thirty cycles were carried
out using the following conditions, 94 °C for 30 s, 56 °C for 30 s and
72 °C for 30 s.
Neurite outgrowth assays
Cerebellar neurons isolated from post-natal day 3 rat pups were
cultured over monolayers of parental 3T3 cells in control media or
media supplemented with a recombinant MAG-Fc chimera (R&D
Systems) used at a ﬁnal concentration of 20 mg/ml MAG-Fc. The
monolayers were established for 24 h prior to addition of the neurons
and the cocultures were maintained for approximately 21 h. CD2019
the PKA inhibitor, KT5720 (Sigma) and the PI3K inhibitor, LY294002
(Sigma) were made up at 1000× concentrations in DMSO and were
added at the time of neuronal plating. Following ﬁxation with 4% PFA,
the neurons were immuno-stained with a GAP-43 antibody (a gift
fromGrahamWilkin, Imperial College, dilution of 1:500) and themean
length of the longest neurite per cell was measured for approximately
120–150 neurons as previously described (Williams et al., 2005).
DRG and cortical explants were obtained from adult rats, they
were cultured in cellogen as previously described (Corcoran andMaden, 1999). Three explants per treatment were used. Neurite
outgrowth was assessed 3 days later by immunohistochemistry with
NF200 (Sigma, dilution of 1:200). The average lengths of the neurites
were measured using image-pro plus software. Media consisted of
DMEM-F12 (Invitrogen) containing N2 (Invitrogen) supplemented
with glucose (33 mM) and glutamine (2 mM).
Labelling of CST neurons/tract and immunohistochemistry
Descendent CST axons were anterogradely traced after DCL by
injecting 10% biotin dextran amine (BDA, Mw10K from Molecular
Probes) in PBS into themotor cortex as previously described (Yip et al.,
2006). Six injections were done in the right cortex, (0.5 μl of BDA/
injection point). Animals (n=6 per treatment) were perfused and the
spinal cord was transferred to PBS (plus 0.1% sodium azide) and
embedded in gelatin (10%, 300bloom; Sigma, Poole, UK).Gelatin blocks
were hardened in 4% PFA, and 40 μm free-ﬂoating serial transverse
sections were cut on a vibratome (Leica, Nussloch, Germany) and
collected in 24-well plates containing PBS (plus 0.1% sodium azide).
BDA was detected using the tyramide ampliﬁcation kit (Perkin-
Elmer) coupled with extra-avidin-FITC (Amersham Pharmacia Bio-
tech, UK, 1:500). All BDA-labelled ﬁbres observed within a 1-mm
square grid were counted at measured intervals from 5 mm above to
5 mm below the lesion site by an experimenter, blinded to treatment.
BDA positive axons were counted in every third section (5 sections
per animal at each point analysed, and a total of 40 sections per
animal) at the same medio-lateral distance from the midpoint (as
seen by the central canal).
CST neurons were labelled by retrograde tracing using Fluorogold
(FG,Molecular Probes). Twomicroliters of 5% of FGwas injected 2mm
deep into the cervical spinal cord (C3–C4) at a rate of 0.5 μl/min
(n=3 rats per group). In sham animals FG was injected 0.5 mm
bilateral to the medial line of spinal cord (1 μl per side), and in
lesioned animals FG (2 μl) was injected into the injury. After 14 days
the cortices were ﬁxed for 2 h in 4% PFA, embedded in OCT compound
and stored frozen. Twelve-micrometer sagittal sections were cut and
four sequential slides containing two sections from lateral 3.4 to
3.9 mm (Paxinos and Watson, 2002) were taken for analysis.
Immunohistochemistrywas carried out using anti-rabbit phospho-
Akt (Cell Signalling technology, dilution of 1:100). Secondary antibody
usedwas anti-rabbit Cy3 conjugated (Jackson, used at 1:1000). Images
were captured at 100× magniﬁcation using a Roperscientiﬁc digital
camera.
Measuring lesion volume
The same sections used for CST quantiﬁcation were used, and
every third section analysed by an observer blinded to the
experimental treatment. They were studied under darkﬁeld micros-
copy, and the border of the damaged area was determined. The
outlined area of each animal were subsequently imported into
Microsoft Excel (Seattle, WA), summed, multiplied by the section
thickness, and corrected for the total number of sections.
Behavioural testing
The behavioural tests were carried out as previously described
(Bradbury et al., 2002). Rats (n=6 per treatment group) were ﬁrst
trained for 2 weeks before surgery to perform grid walk and beam
walk; they were then tested by an observer blinded to the
experimental treatment once a week for 5 weeks after lesion.
Graphs and statistics
Graphs were plotted using Sigma plot. Data are expressed as
mean±S.E.M., and statistical analysis was carried out using Student's
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UK). Means, SEM, SD and P values are provided as summary statistics.
Results
CD2019 increases RARβ expression in the cortex of CST lesioned rats
We ﬁrst asked if RARβ2, which is known to be involved in axonal
outgrowth (Corcoran et al., 2002; So et al., 2006;Wong et al., 2006),
was present in the adult brain. By RT-PCR, RARβ2 could be detected in
the adult cerebellum and cortex (Fig. 1A). Since a retinoid is required
to activate the RARβ2/RXR heterodimer, it is possible that the lack of
axonal outgrowth in an CNS injury may in part be associated with
insufﬁcient levels of the appropriate ligand, as previous work has
shown that the retinoid proﬁle of the brain varies during development
and that retinoids show a varied distribution in the adult brain
(Goncalves et al., 2009;Horton and Maden, 1995). In order to
investigate this we asked if the administration of CD2019 in vivo
could upregulate the receptor in the injured CST neurons. Adult rats
received a cervical (C4) DCL and at the time of injury 180 ng/kg/day
of CD2019 was administered into the lateral ventricle by an osmotic
minipump for 14 days. In the non-lesioned vehicle-treated cerebral
cortices some RARβ protein could be detected, which increased 3-fold
in response to the lesion. However, following treatment with the
RARβ agonist there was a 4-fold increase in the non-lesion and 6-fold
increase in the lesion treated compared to the control animals (Figs.
1B and C).
Fourteen days after surgery and CD2019 treatment, explants of
adult cortex and DRG from the lesion site were obtained from theseFig. 1. RARβ2 expression is induced by CD2019 in the adult brain. Rats were treated at the
RARβ2 in normal adult rat cerebellum and cerebral cortex. (B) ByWestern blotting, there is a
compared to the other groups. (C) Quantiﬁcation of RARβ protein in the cortex. Error bars s
animals and other treatments. ⁎Pb0.005, Student's t-test, n=3 from three different animalanimals and cultured in a cellogen matrix for 3 days in serum-free
medium and analysed for neurite outgrowth with NF200. While there
was little or no neurite outgrowth from DRG and cortex from lesioned
vehicle-treated animals (Figs. 2A, C and E) there was signiﬁcant
increase in both neurite number and length fromDRG and cortex from
rats with DCL treated with CD2019 (Figs. 2B, D and E). This shows that
the agonist administered in vivo is freely available to the injured
neurons to induce neurite outgrowth and that in the case of the cortex
an inhibitory environment can be overcome by RARβ signalling.
CD2019 induces neurite outgrowth in vitro via PI3K signalling
We next asked if RARβ signalling could overcome MAG inhibition
of neurite outgrowth. In the presence of MAG-Fc (20 μg/ml) the
amount of neurite outgrowth from cultured P3 cerebellar neurons
was inhibited by approximately 32% (Fig. 3A). This inhibition was
completely overcome, in a dose-dependent manner by CD2019 (Fig.
3A). Pathways that are known to stimulate neurite outgrowth include
cyclic AMP (cAMP)-dependent protein kinase A (PKA) and phosphoi-
nositide 3-kinase (PI3K), and these are able to overcome myelin
inhibition (Cai et al., 2001; Williams et al., 2005). Therefore, we asked
if the RARβ signalling pathwaywas linked to either of these pathways.
Whereas the ability of CD2019 (1 μM) to circumventmyelin inhibition
was only slightly attenuated by the PKA inhibitor, KT5720 (Fig. 3B), it
was signiﬁcantly blocked by the PI3K inhibitor, LY294002 (Fig. 3B).
Western blots of cerebellar cultures treated with 1 μM CD2019
showed a signiﬁcant 4-fold increase in phospho-Akt, but not total Akt,
a target of PI3K, compared to control cultures (Fig. 3C). This suggests
that CD2019 acts via the PI3K pathway in stimulating neuritetime of lesion by i.c.v. with 180 ng/kg CD2019/day for 14 days. (A) RT-PCR analysis of
n increase in the amount of RARβ protein detected in the cortex of CD2019-treated rats
how SEM, asterisks denote signiﬁcant difference between non-lesioned vehicle-treated
s for each treatment group.
Fig. 2. Neurite outgrowth is stimulated from cortex and DRG explants obtained from lesioned animals treated with CD2019. Animals were treated at the time of lesion by i.c.v. with
180 ng/kg CD2019/day for 14 days. Neurite outgrowth from explants of (A) cortex from lesion animals plus vehicle, (B) cortex from lesion animals treated with CD2019, (C) DRG
from the region of the lesion treated with vehicle, (D) DRG from the region of the lesion treated with CD2019, (E) quantiﬁcation of neurite outgrowth. There are signiﬁcantly more
neuritis, and their lengths are longer from explants of both cortex and DRG obtained from lesioned animals treated with CD2019 compared to vehicle-treated ones. Error bars show
SEM, asterisks denote signiﬁcant difference between vehicle and CD2019 treatment. ⁎Pb0.005, Student's t-test, n=3 explants from three different animals. Scale bar: 100 μm.
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pool of Akt.
CD2019 induces PI3K signalling in cultured cerebellar neurons and in
lesioned CST neurons
We next asked if CD2019 could induce phospho-Akt expression in
the cortex of the CST lesioned animals. The same in vivo dose of drug
was used as above and administered for 14 days. By Western blotting
very low amounts of phospho-Akt were detected in the non-lesioned
vehicle-treated animals, and this was not increased in the vehicle-
treated lesioned or non-lesioned CD2019-treated animals. However,
in the lesioned CD2019-treated animals there was an 8-fold increase
in the amount of phospho-Akt compared to the lesioned vehicle-
treated (Figs. 4A and B).
In order to conﬁrm that phospho-Akt was induced by CD2019 in
the injured CST neurons, they were retrogradedly labelled with
Fluorogold (Figs. 4C–E) at the time of injury and analysed 2 weeks
later. By immunohistochemistry, phospho-Akt was not detected in
the CST neurons of the vehicle-treated rats (Figs. 4D–F) but was co-localised in the CST lesioned neurons of the CD2019-treated animals
(Figs. 4G–I). These data indicate that RARβ signalling is acting via
PI3K/Akt signalling pathway, as we have shown in vitro and that this
only occurs in the injured neurons.
CD2019 induces axonal outgrowth from lesioned CST neurons
We next repeated our in vivo experiment with the same dosing
regime of CD2019 as above. At 5 weeks after surgery, rats were
examined for axonal outgrowth by BDA labelling. In lesioned
vehicle-treated rats (Figs. 5A–G), BDA-labelled CST axons could be
detected rostral to the injury within the CST and collaterals
branching out into the grey matter (Figs. 5A–G). Caudal to the
injury site, no BDA-labelled ﬁbres were found in the CST, but some
were present in the grey matter, which are likely to be collaterals of
the CST axons intact above the lesion (Figs. 5D–G). In contrast, in
lesioned CD2019-treated rats (Figs. 5H–N), BDA-labelled CST axons
were detected growing around the lesion and into the white matter
adjacent to the lesion site caudally (Figs. 5I and J) and proximal to
the site of injury (Fig. 5K). Beyond the lesion many BDA-labelled CST
Fig. 3. CD2019 stimulates neurite outgrowth of cerebellar neurons in the presence of MAG via PI3K signalling. (A) CD2019 overcomes MAG inhibition. Cerebellar neurons were
cultured over monolayers of 3T3 cells in control media (open bars) or media supplemented with the MAG-Fc at 20 μg/ml (black bars) for 21 h. In the absence of CD2019, MAG
inhibits neurite outgrowth, but with increasing concentration of CD2019 this inhibition is overcome. (B) CD2019 induced loss of inhibition is counteracted by the presence of a PI3K
inhibitor (LY294002 at 10 μM) but not a PKA inhibitor (KT5720 at 200 nM). (C) Western blot for phospho-Akt and total Akt and quantiﬁcation. In CD2019-treated cultures there is
4-fold induction of phospho-Akt compared to control cultures but no signiﬁcant increase in total Akt. Data is representative of three different cultures. Error bar shows SEM.
⁎Pb0.005, Student's t-test.
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white matter and into the grey matter (Figs. 5L–N). At the forelimb
innervation ﬁeld many axons were located in the grey matter and
CST axons could be seen growing both longitudinally and tangen-
tially compared to vehicle-treated animals (Fig. 5N). While no
descending CST axons could be detected in the lesion site of vehicle-
treated animals (Fig. 5O), they were present in the CD2019-treated
animals (Figs. 5P, Q) suggesting that it facilitates axonal outgrowth
inside an inhibitory environment.
CD2019 does not affect tissue or axonal sparing but increases axonal
outgrowth
Measurement of lesion volume 6 weeks after lesion showed there
was no signiﬁcant difference between the CD2019 and vehicle-treated
lesioned cords (Fig. 6A), suggesting that RARβ signalling does not
prevent tissue sparing, ruling out this as a reason to explain axonal
outgrowth in the CD2019-treated animals. We next counted the
number of BDA-labelled axons both in the white and grey matters.
There were no signiﬁcant differences in the number of BDA-labelled
axons at 5000 μm rostral to the lesion in both vehicle and CD2019-
treated animals (Fig. 6B) or at 10 μm rostral to the lesion (Fig. 6B). This
suggests that RARβ signalling does not have an effect on axonal
sparing. At increasing distances caudal to the lesion the number of
BDA-labelled axons in the CD2019-treated animals increased signif-
icantly compared to the vehicle-treated ones (Fig. 6B). At 2800 μm
beyond the lesion, which is the level of forelimb innervation, there
was a signiﬁcant peak in the number of BDA-labelled axons in
CD2019-treated animals compared to vehicle-treated animals (Fig.
6B). These data suggest that the RARβ signalling induces axonal
outgrowth.CD2019 induces functional forelimb recovery in CST lesioned rats
To assess forelimb recovery, rats were tested once a week in
behavioural tasks, which measured sensorimotor function over a
period of 5 weeks after lesion. Non-lesioned vehicle-treated rats made
virtually no footslips during the 5-week period when they walked
across a narrow grid or beam (Figs. 7A and B) neither did non-
lesioned rats administered with the RARβ agonist (data not shown).
CST lesioned rats treated with the vehicle made signiﬁcantly more
footslips on the grid and beam throughout the course of the
experiment (5 weeks) compared to vehicle-treated non-lesioned
rats (Figs. 7A and B). In contrast, CST lesioned rats treated with
CD2019 showed functional recovery on the grid 4 weeks post-lesion
and 2 weeks post-lesion on the beam, as the number of foot slips were
no longer signiﬁcantly different to vehicle-treated non-lesioned rats
at these two time points (Figs. 7A and B).
Discussion
Our results suggest that one reason for failure of axonal outgrowth
in the injured CNS is that there is loss of RA-driven signalling
pathways and that this arises because of a lack of appropriate ligand to
activate RARβ2/RXR heterodimers. Recently it has been shown that
the distribution of retinoids varies at different stages of development
and in different parts of the brain (Goncalves et al., 2009; Horton and
Maden, 1995). Genes associated with axonal regeneration may be
upregulated in response to CST lesions, as some sprouting of the
neurons occurs without any further intervention (Caroni and Schwab,
1988; Schnell and Schwab, 1990). We have shown here that RARβ2 is
induced in response to injury, but it is only when the ligand is present
that axonal outgrowth and functional recovery of the forelimb occurs.
Fig. 4. CD2019 induces phospho-Akt expression in CST neurons of lesioned rats. Rats were treated at the time of lesion by i.c.v. with 180 ng/kg of CD2019/day for 14 days. Western
blotting of phospho-Akt (A) and quantiﬁcation (B). In the cortex of the lesioned rats treated with CD2019 phospho-Akt is induced 8-fold compared to vehicle-treated. (C–G) FG and
phosho-Akt labelling of the CST neurons, (C) low power of FG labelling of layer V of the cortex, (D–F) in vehicle-treated brains there is lack of phospho-Akt expression in the CST
neurons, (G–I) in contrast in CD2019-treated brains phospho-Akt is induced in the CST neurons. Error bars show SEM, asterisks denote signiﬁcant difference between vehicle and
CD2019 treatment. ⁎Pb0.005, Student's t-test, n=3 from three different animals. Scale bar=50 μm.
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neurons themselves in the lesioned animals, as the promoter of the
RARβ gene contains a RARE which can bind RARβ2 and thus
autoregulate itself (Leid et al., 1992). CD2019 can be administered
at the time of spinal cord injury, and as it is a small lipophilic molecule,
it can reach all the injured neurons which express RARβ2. This
includes the DRG (Corcoran et al., 2000; Corcoran and Maden, 1999;
So et al., 2006), and we have shown here that explants of DRG from
CD2019-treated lesioned animals have enhanced neurite outgrowth.
Retinoids including RARβ agonists have also been shown to stimulateFig. 5. CD2019 promotes growth of CST axons following lesion. Rats were treated at the tim
later. Axonal outgrowthwas determined with BDA tracing in longitudinal sections of spinal co
axons were apparent along the CST, rostral to the injury (A–C), but absent caudal to it (D–G)
or diverting away (F–G, arrowheads) from the white matter region of the injured CST. In con
site (H). Proximal to the lesion, BDA ﬁbres (arrows) can be seen growing around the lesion
(K). Caudally to the injured CST, BDA-labelled ﬁbres can be seen growing longitudinally wit
matter of the forelimb innervation ﬁeld many axons can be seen (N). Saggital sections of the
(O), in contrast in CD2019-treated animals axonal outgrowth (arrows) is observed in th
bars=500 μm (A–N), 100 μm (O–Q).proliferation and differentiation of neural progenitor cells (Goncalves
et al., 2005, 2009; Haskell and LaMantia, 2005; Wang et al., 2005).
Thus other RARβ responsive neural cells may contribute to the
functional recovery we see in the CD2019-treated lesioned animals.
In addition some of the behavioural recovery we see in the
CD2019-treated lesioned rats may occur from increased sprouting
from spared axons. The model we have used here the DCL is known to
leave the ventral CST intact. This makes up about 5% of the total CST
and undergoes collateral sprouting leading to spontaneous functional
recovery in models of spinal cord injury (Weidner et al., 2001). As 65%e of lesion by i.c.v. with 180 ng/kg CD2019/day for 14 days and then analysed 28 days
rd rostral (left) and caudal (right) to the lesion site. In vehicle-treated rats BDA-labelled
. BDA-labelled ﬁbres can be seen in adjacent grey matter, running parallel (D, E, arrows)
trast, CD2019-treated rats exhibited BDA-labelled ﬁbres in the CST caudal to the lesion
site through the grey matter (I-J) and within the white matter region of the injured CST
hin (arrows) or tangentially (arrowheads) to the white matter tract (L–N). In the grey
lesion site (O–Q), in vehicle-treated animals axons cannot be detected in the lesion site
e lesion site (P,Q). Black lines indicate the rostral part of the lesion for O–Q. Scale
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Fig. 6. CD2019 does not affect lesion volume but promotes growth of CST axons. Rats
were treated at the time of lesion by i.c.v. with 180 ng/kg CD2019/day for 14 days and
then analysed 28 days later. (A) The lesion volumes are similar in both CD2019 and
vehicle-treated rats, suggesting that CD2019 does not alter tissue sparing. (B)
quantiﬁcation of axonal outgrowth in sagittal sections of the injured cord. In the
CD2019-treated animals there is a signiﬁcant increase in the number of labelled BDA
axons (empty bars) beyond the lesion at all distances compared to the vehicle-treated
lesioned animals. Error bars show s.d. ⁎Pb0.05, ⁎⁎Pb0.005, Student's t-test, n=6 rats
for each treatment group. Asterisks denote signiﬁcant difference between vehicle and
CD2019 treatment.
154 M. Agudo et al. / Neurobiology of Disease 37 (2010) 147–155of human spinal cord injuries are incomplete lesions, any factor that
can increase axonal sprouting may be beneﬁcial (Raineteau and
Schwab, 2001).
The administration of CD2019 is a simpler approach than using
lentiviral vectors overexpressing RARβ2 (Wong et al., 2006; Yip et al.,
2006) for axonal outgrowth and overcomes three major disadvan-
tages. Firstly, the vector may not transduce all injured neurons,
secondly, it may insert randomly into the genome causing deleterious
effects, and thirdly, it cannot be switched off once it has carried out it's
role in neuronal repair. It remains to be shown at what other time
points after spinal cord injury if CD2019 can give axonal outgrowth
and the optimal dosing period.
CD2019 can promote neurite outgrowth within the MAG inhibi-
tory environment in vitro. While we have not directly shown what
axonal inhibitory pathways are overcome by CD2019 in vivo, it does
act as in vitro via PI3K signalling suggesting that this pathway is
essential for axonal outgrowth. The PI3K signalling pathway has been
shown to be involved in neurotrophin-mediated axonal elongationFig. 7. CD2019 induces functional recovery of the forelimb in lesioned animals. Rats
were treated at the time of lesion by i.c.v. with 180 ng/kg CD2019/day for 14 days. (A)
In a grid and (B) beam test, CD2019-treated lesioned rats showed functional recovery
4weeks post-lesion in a grid task and 2weeks post-lesion in a beam task, whereas there
was no signiﬁcant recovery in the vehicle-treated lesioned animals. Error bar shows
SEM. Asterisks denote signiﬁcant difference between the lesioned treated (CD2019 or
vehicle) and non-lesioned vehicle-treated group ⁎Pb0.05, Student's t test, n=6 rats for
each treatment group.and guidance (Atwal et al., 2000; Ming et al., 1999). One of the
downstream targets of this pathway is phospho-Akt, and we have
shown here that it increases in response to RARβ signalling both in
cultured neurons and the lesioned neurons in vivo, suggesting that
the same pathway operates both in vivo and in vitro. A similar
activation of the PI3K pathway by retinoids has also been shown in
neuroblastoma and MCF-7 cells and this requires the presence of a
cytoplasmic located RAR which interacts directly with PI3K (Lopez-
Carballo et al., 2002; Ohashi et al., 2009).
We have shown here that phospho-Akt accumulates in the
neuronal cell bodies of the CST which are located in the cortex,
these are the neurons which are injured in our model of spinal cord
injury. It is interesting to note that phospho-Akt is only upregulated
by CD2019 in the injured neurons. Previous data has also shown the
importance of Akt signalling in neurite outgrowth. In vivo loss of Akt
signalling leads to defects in neurite outgrowth from the cortex and
this is due to defects of laminin γ1 expression (Chen et al., 2009). The
induction of phospho-Akt also occurs in neuronal cell bodies and the
axonal growth cones in response to NGF (Zhou et al., 2004), and it has
previously been shown that NGF can stimulate RARβ signalling
(Corcoran and Maden, 1999).
One therapeutic option for spinal cord injury is to prevent the
wave of secondary cell death which increases the size of the lesion
(Giulian and Robertson, 1990; Means and Anderson, 1983; Tator and
Fehlings, 1991). Such tissue sparing occurs when Schwann cells or
olfactory ensheathing cells are grafted into the lesion (Ruitenberg
et al., 2003; Takami et al., 2002). However, CD2019 does not increase
tissue sparing as the lesion volumes are not signiﬁcantly different
between agonist and vehicle-treated animals. Nor does CD2019
increase axonal sparing which can lead to functional recovery (Pearse
et al., 2004), as there is no signiﬁcant difference with the vehicle-
treated animals in the number of axons at either 5000 or 10 μm rostral
to the lesion.
Various treatments for spinal cord injury have been proposed,
including growth factors (Murray et al., 2004), anti-inﬂammatory
molecules (Eng and Lee, 2003), stem cells (Myckatyn et al., 2004) and
gene therapy (Romano, 2003). We propose that retinoids are another
potential treatment, and they have the distinct advantage in that they
are easily administered to the injured neurons, as they are small
lipophilic molecules which can cross the blood brain barrier.
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